American Journal of Cardiology
Volume 96, Issue 10 , Pages 1361-1364, 15 November 2005

Effect of Intensive Versus Moderate Lipid Lowering on Endothelial Function and Vascular Responsiveness to Angiotensin II in Stable Coronary Artery Disease

  • Pim van der Harst, MD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel: 31-50-361-2810; fax: 31-50-363-2812.
  • ,
  • Lodewijk J. Wagenaar, MD, PhD

      Affiliations

    • Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
  • ,
  • Hendrik Buikema, PhD

      Affiliations

    • Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • ,
  • Adriaan A. Voors, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • ,
  • H.W. Thijs Plokker, MD, PhD

      Affiliations

    • Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
  • ,
  • Wim J. Morshuis, MD, PhD

      Affiliations

    • Department of Thorax Surgery, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
  • ,
  • A. Jacob Six, MD, PhD

      Affiliations

    • Department of Cardiology, Hofpoort Hospital, Woerden, The Netherlands
  • ,
  • Piet W. Boonstra, MD, PhD

      Affiliations

    • Department of Cardiothorax Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • ,
  • Georg Nickenig, MD

      Affiliations

    • Klinik und Poliklinik Innere Medizin III, Universitat des Saarlandes, Homburg, Germany.
  • ,
  • Sven Wassmann, MD

      Affiliations

    • Klinik und Poliklinik Innere Medizin III, Universitat des Saarlandes, Homburg, Germany.
  • ,
  • Dirk J. van Veldhuisen, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • ,
  • Wiek H. van Gilst, PhD

      Affiliations

    • Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Received 11 May 2005; received in revised form 7 July 2005; accepted 7 July 2005. published online 19 September 2005.

Recent evidence has demonstrated that intensive lipid-lowering therapy with a high-dose statin provides significant clinical benefit beyond moderate lipid-lowering therapy. However, dose-dependent effects of short-term statin therapy on vascular function have not been demonstrated. We studied endothelial function and vascular responsiveness to angiotensin II in patients who had coronary artery diseased and were randomized to receive low- or high-dose atorvastatin (10 or 80 mg, respectively) or placebo. Internal thoracic artery segments were obtained during coronary bypass surgery and studied in vitro. Endothelium-dependent vasodilation was increased with atorvastatin therapy (p = 0.035) but was significantly increased further in patients who received 80 mg compared with those who received 10 mg of atorvastatin (p = 0.05). Endothelium improvement was accompanied by decreased vascular response to angiotensin II (p = 0.039). These findings suggest a mechanism for the clinical benefit of intensive lipid-lowering treatment in coronary heart disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported in part by a grand from Pfizer, Cappelle a/d IJssel, The Netherlands; Dr. van der Harst is supported by ZON-MW (920-03-236) of The Netherlands Organisation for Health Research and Development, The Netherlands; and Dr. van Veldhuisen received Grant D97-017 from the Netherlands Heart Foundation, The Netherlands.

PII: S0002-9149(05)01357-3

doi:10.1016/j.amjcard.2005.07.052

American Journal of Cardiology
Volume 96, Issue 10 , Pages 1361-1364, 15 November 2005